Skip to main content
. 2021 Aug 26;8(4):1603–1616. doi: 10.1007/s40744-021-00360-6

Table 1.

Profile of included trial participants, grouped by intervention received

Anti-IL-17 Anti-TNF Placebo
Mean age (years) 45.7 42.9 43.8
Male (%) 63.2 65.1 64.5
White/European (%) 82.3 70.7 74.7
Past IBD excluded by trial (%) 0 3.2 2.1
Active IBD excluded by trial (%) 35.5 16.9 22.9
Median trial period (weeks) 16 16 16